The German support announcement was certainly a po
Post# of 15624
We're looking for more news on trials, both preclinical efficacy trials and the FDA listed Phase 1 safety trial.
We're looking for news of a U.S. strategy for marketing products now that the Medmar agreement has been terminated.
We're looking for more information on the sublingual tablets and other products approaching the marketplace as cannabis based meds that may be sold in medical marijuana stores without substantial additional clinical trials.
We're looking for further information on out Patent's working through the system for International Approval.
Most importantly, we're looking for sales in any country where our psoriasis cream can now be purchased.
I believe we're at a period of the company's development where all the above should be addressed in the next three months. Each of these things individually ought to be worth a share price increase of somewhere between a nickle, and a quarter. Combined I believe we see a market cap of at least half a billion, I.E. about $3.50. Remember, I'm saying that that would be for the completion of all of the above, and it needs to be done in a manner that Investor's questions are answered, not where the announcement leaves more questions than it answers.
Gary